NOVUS Buy Hold or Sell Recommendation

<div class='circular--portrait' style='background:#CD0D74;color: white;font-size:3em;padding-top: 40px;;'>NDE</div>
NDEV -- USA Stock  

USD 0.0372  0.0001  0.27%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding NOVUS ACQUISITION DEVELOPMENT is 'Strong Sell'. Macroaxis provides NOVUS ACQUISITION buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NDEV positions. The advice algorithm takes into account all of NOVUS ACQUISITION available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from NDEV buy-and-hold perspective. Additionally, see NOVUS ACQUISITION Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Strong Sell


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Not Available
For the selected time horizon NOVUS ACQUISITION DEVELOPMENT has a mean deviation of 10.78, semi deviation of 14.05, standard deviation of 15.72, variance of 247.12, downside variance of 232.67 and semi variance of 197.36
We provide buy, hold, or sell recommendation to complement the last-minute expert consensus on NOVUS ACQUISITION DEVELOPMENT. Our dynamic recommendation engine harnesses multi - dimensional algorithm to analyze the entity potential to grow using all technical and fundamental data available at this particular time. To make sure NOVUS ACQUISITION is not overpriced, please verify all NOVUS ACQUISITION DEVELOPMENT fundamentals, including its Cash Flow from Operations as well as the relationship between Total Asset and Z Score . As NOVUS ACQUISITION appears to be a penny stock we also strongly suggest to check its Price to Sales numbers.

NOVUS ACQUISITION Trading Alerts and Improvement Suggestions

NOVUS ACQUISITION appears to be very risky and stock price may revert if volatility continues
NOVUS ACQUISITION has some characteristics of a very speculative penny stock
Latest headline from www.nature.com: DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis - Nature.com

NOVUS ACQUISITION Returns Distribution Density

Mean Return1.06Value At Risk22.84
Potential Upside21.68Standard Deviation15.72
 Return Density 


Alpha over DOW
Beta against DOW=1.36
Overall volatility
Information ratio =0.08


NOVUS ACQUISITION DEVELOPMENT is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about NOVUS ACQUISITION implied risk. NOVUS ACQUISITION DEVELOPMENT is a penny stock. Although NOVUS ACQUISITION may be in fact a good investment, many penny stocks are subject to artificial stock hype. Make sure you completely understand upside potential and downside risk of investing in NOVUS ACQUISITION DEVELOPMENT. We encourage investors to look for the signals such us message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
 Better Than Average     
 Worse Than Average Compare NOVUS ACQUISITION to competition

NOVUS ACQUISITION Fundamental Vs Peers

FundamentalsNOVUS ACQUISITIONPeer Average
Profit Margin24.53 (1.27) 
Operating Margin35.04 (5.51) 
Current Valuation3.47 M16.62 B
Shares Outstanding97.85 M571.82 M
Price to Earning3.10 28.72 
Price to Book2.33 9.51 
Price to Sales37.67 11.42 
Revenue96.76 K9.43 B
Gross Profit92.87 K27.38 B
Net Income23.73 K570.98 M
Cash and Equivalents106.27 K2.7 B
Total Debt99.05 K5.32 B
Debt to Equity6.50 48.70 
Book Value Per Share0.02 1.93 K
Cash Flow from Operations12.01 K971.22 M
Earnings Per Share0.012 3.12 
Number of Employees118.84 K
Market Capitalization3.65 M19.03 B
Total Asset791 K29.47 B
Retained Earnings(6 M)9.33 B
Working Capital35 K1.48 B
Current Asset150 K9.34 B
Current Liabilities115 K7.9 B
Z Score11.88.72